Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
171
Active, not recruiting, industry sponsors, Hematology and blood cancers, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting286
- Completed1,361
171 trials
Showing 1 to 25, recently updated first.
- A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaActive, not recruiting
Kyowa Kirin Co., Ltd.Industry
NCT07623616 · 6 participants (planned) · Start Apr 23, 2026 · Primary completion Mar 2027
Drug: ziftomenib · For: Acute Myeloid Leukemia (AML)
Sites: Chiba, Japan; Gifu, Japan; Hyōgo, Japan · 20 sites in all
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell MalignanciesActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05207670 · 320 participants · Start Feb 1, 2022 · Primary completion Oct 1, 2027
Drug: Mosunetuzumab (Cohorts A-C); Mosunetuzumab (Cohorts D-E) and 1 more · For: Non-Hodgkin Lymphoma
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 39 sites in all
- A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin LymphomaActive, not recruiting
TakedaTakeda (TAK)
NCT02979522 · 59 participants · Start Sep 6, 2017 · Primary completion May 5, 2020
Drug: Brentuximab vedotin; Doxorubicin and 2 more · For: Hodgkin Disease
Sites: Aurora, Colorado; Cincinnati, Ohio; Salvador, Brazil · 14 sites in all
- Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)Active, not recruiting
Cellectis S.A.Industry
NCT04150497 · 45 participants · Start Oct 14, 2019 · Primary completion Sep 16, 2026
Drug: UCART22; CLLS52 · For: B-cell Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 20 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT06524375 · 118 participants · Start Aug 9, 2024 · Primary completion Oct 28, 2026
Drug: Venetoclax; cBTKi Monotherapy · For: Chronic Lymphocytic Leukemia
Sites: Springdale, Arkansas; Aurora, Colorado; Jacksonville, Florida · 20 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04077723 · 498 participants (planned) · Start Aug 13, 2019 · Primary completion Dec 28, 2026
Drug: Englumafusp alfa; Obinutuzumab and 2 more · For: Lymphoma, Non-Hodgkin
Sites: Pasadena, California; San Francisco, California; St Louis, Missouri · 35 sites in all
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04925479 · 46 participants · Start Dec 27, 2021 · Primary completion Sep 3, 2027
Drug: Asciminib Pediatric formulation group; Asciminib Adult formulation group · For: Myeloid Leukemia, Philadelphia Positive
Sites: Indianapolis, Indiana; Boston, Massachusetts; New York, New York · 23 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05828511 · 148 participants · Start Dec 19, 2023 · Primary completion Nov 2, 2035
Drug: Linvoseltamab · For: Multiple Myeloma
Sites: Los Angeles, California; Orange, California; Denver, Colorado · 32 sites in all
- Study of Oral MRT-2359 in Selected Cancer PatientsActive, not recruiting
Monte Rosa Therapeutics, IncIndustry
NCT05546268 · 174 participants (planned) · Start Oct 12, 2022 · Primary completion Dec 2026
Drug: Oral MRT-2359; Oral MRT-2359 and 4 more · For: NSCLC; SCLC; High Grade Neuroendocrine Cancer and 5 more
Sites: Scottsdale, Arizona; San Diego, California; New Haven, Connecticut · 17 sites in all
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)Active, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT04703192 · 155 participants · Start Jun 3, 2021 · Primary completion May 10, 2023
Drug: Valemetostat Tosylate · For: Relapsed/Refractory Peripheral T-Cell Lymphoma; Adult T Cell Leukemia/Lymphoma
Sites: Duarte, California; Palo Alto, California; San Francisco, California · 60 sites in all
GenmabIndustry
NCT05201248 · 49 participants · Start Mar 10, 2022 · Primary completion Oct 2027
Drug: Epcoritamab; Cyclophosphamide and 5 more · For: B-Cell Non-Hodgkin Lymphoma
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 18 sites in all
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03407144 · 340 participants (planned) · Start Apr 9, 2018 · Primary completion Feb 12, 2027
Drug: pembrolizumab; doxorubicin and 7 more · For: Hodgkin Lymphoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 93 sites in all
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaActive, not recruiting
GenmabIndustry
NCT03625037 · 666 participants · Start Jun 26, 2018 · Primary completion Jan 2029
Drug: Epcoritamab · For: DLBCL; High-grade B-cell Lymphoma (HGBCL); Primary Mediastinal Large B-cell Lymphoma (PMBCL) and 6 more
Sites: Phoenix, Arizona; San Francisco, California; Denver, Colorado · 85 sites in all
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeActive, not recruiting
GenmabIndustry
NCT04623541 · 194 participants · Start Nov 25, 2020 · Primary completion Dec 2027
Drug: Epcoritamab; Epcoritamab and 7 more · For: Relapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome and 1 more
Sites: Birmingham, Alabama; California City, California; Duarte, California · 81 sites in all
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)Active, not recruiting
GenmabIndustry
NCT04542824 · 78 participants · Start Aug 20, 2020 · Primary completion Sep 2027
Drug: Epcoritamab (monotherapy); Epcoritamab and 4 more · For: Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma and 3 more
Sites: Sendai, Japan; Aichi, Japan; Chiba, Japan · 15 sites in all
- A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06550895 · 11 participants · Start Sep 16, 2024 · Primary completion Aug 26, 2027
Drug: Cilta-cel; Talquetamab · For: Multiple Myeloma
Sites: Iowa City, Iowa; Louisville, Kentucky; Detroit, Michigan · 9 sites in all
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruiting
GenmabIndustry
NCT04663347 · 543 participants · Start Nov 3, 2020 · Primary completion Sep 30, 2027
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; rituximab and lenalidomide and 16 more · For: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 57 sites in all
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05421663 · 166 participants · Start Aug 12, 2022 · Primary completion Jul 30, 2041
Drug: JNJ-90014496 · For: Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse
Sites: Duarte, California; Denver, Colorado; Iowa City, Iowa · 32 sites in all
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04133636 · 208 participants · Start Nov 7, 2019 · Primary completion Feb 26, 2027
Drug: JNJ-68284528; Lenalidomide and 3 more · For: Multiple Myeloma
Sites: San Diego, California; San Francisco, California; New Haven, Connecticut · 47 sites in all
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07266441 · 168 participants · Start Feb 8, 2026 · Primary completion Jun 14, 2027
Drug: JNJ-79635322 · For: Multiple Myeloma
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 71 sites in all
- A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaActive, not recruiting
EnteromeIndustry
NCT04669171 · 80 participants (planned) · Start Jul 5, 2021 · Primary completion May 30, 2029
Drug: EO2463; lenalidomide and 1 more · For: Follicular Lymphoma; Marginal Zone Lymphoma
Sites: Boston, Massachusetts; Rochester, Minnesota; Rochester, New York · 11 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06577025 · 43 participants · Start Aug 20, 2024 · Primary completion Sep 2, 2030
Drug: Cilta-cel; Talquetamab and 7 more · For: Multiple Myeloma
Sites: Duarte, California; San Francisco, California; Iowa City, Iowa · 16 sites in all
- A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05963074 · 333 participants · Start May 30, 2024 · Primary completion Dec 15, 2027
Drug: Ibrutinib; Venetoclax · For: Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma
Sites: Cerritos, California; Los Alamitos, California; San Luis Obispo, California · 74 sites in all
- A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple MyelomaActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05535244 · 90 participants (planned) · Start Oct 17, 2022 · Primary completion Feb 26, 2027
Drug: Cevostamab; Tocilizumab · For: Multiple Myeloma
Sites: Aurora, Colorado; Jacksonville, Florida; Baltimore, Maryland · 27 sites in all
- Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)Active, not recruiting
AmgenAmgen (AMGN)
NCT06054113 · 18 participants · Start Jul 23, 2024 · Primary completion Jan 6, 2026
Drug: Blinatumomab · For: B Precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Sites: Hefei, China; Chongqing, China; Guangzhou, China · 7 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.